Zealand Pharma A/S
Smedeland 26 B
Glostrup
DK-2600
Tel: 45-43-28-12-00
Fax: 45-43-28-12-12
Website: http://www.zp.dk/
Email: info@zp.dk
294 articles with Zealand Pharma A/S
-
Zealand Pharma Announces Full Year Results for 2022
3/2/2023
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced financial results for the 12-month period from January 1 to December 31, 2022 and provided a corporate update.
-
Correction: Zealand Pharma Announces Full Year Results for 2022
3/2/2023
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced financial results for the 12-month period from January 1 to December 31, 2022 and provided a corporate update.
-
Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022
2/24/2023
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on March 2, 2023 at 2:00 pm CET following the announcement of results for the full year of 2022.
-
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
11/10/2022
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the interim report for the three and nine months ended September 30, 2022 and provided a corporate update.
-
Zealand Pharma to Participate in Upcoming November 2022 Investor Conferences
11/8/2022
A Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the company is scheduled to participate in the following investor conferences in November.
-
Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
11/3/2022
A Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 10, 2022 at 4 pm CET following the announcement of results for the third quarter of 2022.
-
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
11/1/2022
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced presentations at the Obesity Society Annual Meeting being held in San Diego, California from November 1-4, 2022.
-
Zealand Pharma major shareholder announcement: Polar Capital
10/11/2022
Zealand Pharma A/S announces the receipt on 11 October 2022 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
-
Zealand Pharma major shareholder announcement: Van Herk Investments
10/10/2022
Zealand Pharma A/S announces the receipt of notification dated 10 October 2022 pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
-
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
9/30/2022
Zealand Pharma A/S announced positive topline results from the pivotal Phase 3 trial of glepaglutide, a long-acting GLP-2 analogue designed for once or twice weekly subcutaneous delivery via auto-injector, in patients with short bowel syndrome.
-
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
9/30/2022
Zealand Pharma A/S, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
-
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
9/21/2022
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58 th Annual Meeting of the European Association for the Study of Diabetes (EASD).
-
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
9/19/2022
Zealand Pharma A/S announced that clinical results from the two-part Phase 3 trial of dasiglucagon for the treatment of congenital hyperinsulinism in newborns and infants up to 12 months of age were presented at the 60th annual European Society for Paediatric Endocrinology meeting, held in Rome, September 15-17, 2022.
-
The past week saw promising developments in candidate therapies for cancer, congenital hyperinsulinism, chronic cough and COVID-19 vaccines.
-
Zealand Pharma grants warrants to employees in Denmark - September 13, 2022
9/13/2022
Zealand Pharma A/S announces granting of warrants to employees in accordance with Zealand's Remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on April 6, 2022.
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
9/7/2022
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.
-
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
9/7/2022
Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® for injection.
-
Total number of shares and voting rights in Zealand Pharma at August 31, 2022
8/31/2022
Zealand Pharma A/S announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
-
This week's Movers & Shakers includes Tessa and Adial bringing in new CEOs, while other companies strengthened their regulatory and medical teams with key appointments